What is William Blair’s Estimate for TENX FY2028 Earnings?

Tenax Therapeutics, Inc. (NASDAQ:TENX) – Research analysts at William Blair issued their FY2028 earnings per share estimates for shares of Tenax Therapeutics in a research note issued on Wednesday, May 14th. William Blair analyst M. Phipps forecasts that the specialty pharmaceutical company will post earnings of ($1.85) per share for the year. William Blair has a “Outperform” rating on the stock. The consensus estimate for Tenax Therapeutics’ current full-year earnings is ($0.88) per share.

Tenax Therapeutics (NASDAQ:TENX) last released its quarterly earnings results on Wednesday, May 14th. The specialty pharmaceutical company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.48) by $0.20.

TENX has been the topic of several other reports. StockNews.com started coverage on Tenax Therapeutics in a report on Friday. They set a “sell” rating on the stock. Leerink Partners set a $20.00 price objective on Tenax Therapeutics in a report on Monday, March 10th. One research analyst has rated the stock with a sell rating, three have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $18.00.

Tenax Therapeutics Stock Performance

Tenax Therapeutics stock opened at $5.89 on Friday. The stock’s 50 day moving average price is $5.86 and its 200 day moving average price is $5.91. The firm has a market capitalization of $24.43 million, a PE ratio of -2.38 and a beta of 1.92. Tenax Therapeutics has a one year low of $2.77 and a one year high of $7.89.

Institutional Investors Weigh In On Tenax Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Geode Capital Management LLC increased its holdings in shares of Tenax Therapeutics by 32.4% in the 4th quarter. Geode Capital Management LLC now owns 24,354 shares of the specialty pharmaceutical company’s stock valued at $151,000 after acquiring an additional 5,964 shares during the last quarter. ADAR1 Capital Management LLC increased its holdings in shares of Tenax Therapeutics by 98.1% in the 1st quarter. ADAR1 Capital Management LLC now owns 68,741 shares of the specialty pharmaceutical company’s stock valued at $450,000 after acquiring an additional 34,048 shares during the last quarter. Two Sigma Investments LP bought a new stake in shares of Tenax Therapeutics in the 4th quarter valued at approximately $84,000. Millennium Management LLC bought a new stake in shares of Tenax Therapeutics in the 4th quarter valued at approximately $166,000. Finally, Janus Henderson Group PLC bought a new stake in shares of Tenax Therapeutics in the 4th quarter valued at approximately $1,026,000. 1.67% of the stock is currently owned by hedge funds and other institutional investors.

About Tenax Therapeutics

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.